The fairness of PIPEs, particularly the preferential sharing of confidential, stock-moving information, is now a legal question.
A shareholder is suing Taysha Gene Therapies insiders and a group of health care investment firms for allegedly enriching themselves in a $150 million PIPE transaction that involved delaying the public disclosure of positive results from a gene therapy clinical trial.
The lawsuit, filed earlier this month in the Delaware Court of Chancery, will be closely followed because it potentially upends the sharing of material, nonpublic information between companies and select investors as a mechanism for getting PIPEs transacted.Â
Click this link for the original source of this article.
Author: Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.